Cargando…

Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine

Finding a functional cure for HIV-1 infection will markedly decrease the social and economic burden of this disease. In this work, we have taken advantage of the antigen presenting cell role of human dendritic cells (DCs) to try to induce an immune response to HIV-derived peptide delivered to DCs us...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín-Moreno, Alba, Jiménez Blanco, José L., Mosher, Jamie, Swanson, Douglas R., García Fernández, José M., Sharma, Ajit, Ceña, Valentín, Muñoz-Fernández, María Angeles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407655/
https://www.ncbi.nlm.nih.gov/pubmed/32664555
http://dx.doi.org/10.3390/pharmaceutics12070656
_version_ 1783567671487365120
author Martín-Moreno, Alba
Jiménez Blanco, José L.
Mosher, Jamie
Swanson, Douglas R.
García Fernández, José M.
Sharma, Ajit
Ceña, Valentín
Muñoz-Fernández, María Angeles
author_facet Martín-Moreno, Alba
Jiménez Blanco, José L.
Mosher, Jamie
Swanson, Douglas R.
García Fernández, José M.
Sharma, Ajit
Ceña, Valentín
Muñoz-Fernández, María Angeles
author_sort Martín-Moreno, Alba
collection PubMed
description Finding a functional cure for HIV-1 infection will markedly decrease the social and economic burden of this disease. In this work, we have taken advantage of the antigen presenting cell role of human dendritic cells (DCs) to try to induce an immune response to HIV-derived peptide delivered to DCs using two different polycationic nanoparticles: a G4 PAMAM dendrimer modified to a 70/30 ratio of hydroxyl groups/amines and a cyclodextrin derivative. We have studied peptide delivery using a fluorescence peptide and have studied the immune response generation by cytokine determination and flow cytometry. We have found a robust delivery of the antigenic peptide to DCs and activated dendritic cell-mediated peripheral blood mononuclear cells (PBMCs) proliferation using the mixed lymphocyte reaction. However, no expression of markers indicating activation of either B or T lymphocytes was observed. Moreover, the release of the pro-inflammatory cytokine TNF-α or IL-2 was only observed when DCs treated with either the dendrimer or the dendriplex containing the peptide. Antigenic peptide delivery to DCs is a promising approach to generate a vaccine against HIV-1 infection. However, more studies, including the simultaneous delivery of several antigenic peptides from different viral proteins, can markedly improve the immune response.
format Online
Article
Text
id pubmed-7407655
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74076552020-08-12 Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine Martín-Moreno, Alba Jiménez Blanco, José L. Mosher, Jamie Swanson, Douglas R. García Fernández, José M. Sharma, Ajit Ceña, Valentín Muñoz-Fernández, María Angeles Pharmaceutics Article Finding a functional cure for HIV-1 infection will markedly decrease the social and economic burden of this disease. In this work, we have taken advantage of the antigen presenting cell role of human dendritic cells (DCs) to try to induce an immune response to HIV-derived peptide delivered to DCs using two different polycationic nanoparticles: a G4 PAMAM dendrimer modified to a 70/30 ratio of hydroxyl groups/amines and a cyclodextrin derivative. We have studied peptide delivery using a fluorescence peptide and have studied the immune response generation by cytokine determination and flow cytometry. We have found a robust delivery of the antigenic peptide to DCs and activated dendritic cell-mediated peripheral blood mononuclear cells (PBMCs) proliferation using the mixed lymphocyte reaction. However, no expression of markers indicating activation of either B or T lymphocytes was observed. Moreover, the release of the pro-inflammatory cytokine TNF-α or IL-2 was only observed when DCs treated with either the dendrimer or the dendriplex containing the peptide. Antigenic peptide delivery to DCs is a promising approach to generate a vaccine against HIV-1 infection. However, more studies, including the simultaneous delivery of several antigenic peptides from different viral proteins, can markedly improve the immune response. MDPI 2020-07-11 /pmc/articles/PMC7407655/ /pubmed/32664555 http://dx.doi.org/10.3390/pharmaceutics12070656 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Martín-Moreno, Alba
Jiménez Blanco, José L.
Mosher, Jamie
Swanson, Douglas R.
García Fernández, José M.
Sharma, Ajit
Ceña, Valentín
Muñoz-Fernández, María Angeles
Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine
title Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine
title_full Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine
title_fullStr Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine
title_full_unstemmed Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine
title_short Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine
title_sort nanoparticle-delivered hiv peptides to dendritic cells a promising approach to generate a therapeutic vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407655/
https://www.ncbi.nlm.nih.gov/pubmed/32664555
http://dx.doi.org/10.3390/pharmaceutics12070656
work_keys_str_mv AT martinmorenoalba nanoparticledeliveredhivpeptidestodendriticcellsapromisingapproachtogenerateatherapeuticvaccine
AT jimenezblancojosel nanoparticledeliveredhivpeptidestodendriticcellsapromisingapproachtogenerateatherapeuticvaccine
AT mosherjamie nanoparticledeliveredhivpeptidestodendriticcellsapromisingapproachtogenerateatherapeuticvaccine
AT swansondouglasr nanoparticledeliveredhivpeptidestodendriticcellsapromisingapproachtogenerateatherapeuticvaccine
AT garciafernandezjosem nanoparticledeliveredhivpeptidestodendriticcellsapromisingapproachtogenerateatherapeuticvaccine
AT sharmaajit nanoparticledeliveredhivpeptidestodendriticcellsapromisingapproachtogenerateatherapeuticvaccine
AT cenavalentin nanoparticledeliveredhivpeptidestodendriticcellsapromisingapproachtogenerateatherapeuticvaccine
AT munozfernandezmariaangeles nanoparticledeliveredhivpeptidestodendriticcellsapromisingapproachtogenerateatherapeuticvaccine